我武生物(300357) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥287,495,596.43, a decrease of 7.64% compared to the same period last year[4] - The net profit attributable to shareholders for Q3 2023 was ¥121,543,298.85, down 16.83% year-on-year[4] - The net profit after deducting non-recurring gains and losses was ¥120,438,846.14, a decrease of 13.38% compared to the previous year[4] - Total operating revenue for the current period is CNY 673,790,861.60, a decrease of 3.4% from CNY 700,180,586.99 in the previous period[29] - Basic earnings per share decreased to CNY 0.5160 from CNY 0.6250, reflecting a decline of 17.5%[32] - The total comprehensive income for the current period is CNY 259,789,903.98, down from CNY 318,947,061.08 in the previous period, a decrease of 18.5%[32] - The total profit for the period was 301,462,178.69, compared to 378,516,139.98 in the previous period, indicating a decrease of about 20.4%[48] - The operating profit for the period was 300,587,813.26, compared to 376,374,455.50 in the previous period, showing a decline of around 20.1%[48] Assets and Liabilities - The total assets at the end of the reporting period increased to ¥2,510,657,788.18, representing a growth of 14.23% from the end of the previous year[4] - The total liabilities rose to CNY 242,774,148.81, up from CNY 170,760,022.93, indicating a growth of 42.2%[29] - The total equity attributable to shareholders increased to CNY 2,144,979,896.42 from CNY 1,979,540,771.28, a rise of 8.3%[29] - The cash balance at the end of the period was ¥692,239,701.16, up from ¥452,384,667.95 at the beginning of the year[33] Cash Flow - The net cash flow from financing activities increased by ¥82,320,239.10, a growth of 76.02% year-on-year, mainly due to capital contributions from minority shareholders[8] - The net cash flow from investment activities increased to ¥56,063,321.85, up from ¥30,898,065.63, reflecting a significant improvement[33] - The net cash flow from financing activities was -¥25,972,127.30, compared to -¥108,292,366.40 in the previous period, indicating a reduction in cash outflow[33] - The net increase in cash and cash equivalents for the year-to-date period was ¥281,447,920.66, representing a 62.99% increase compared to the same period last year[37] - The cash inflow from investment activities totaled ¥572,633,570.95, slightly down from ¥585,555,974.38 in the previous period[33] - The cash outflow from financing activities was ¥131,753,727.30, compared to ¥108,292,366.40 previously, indicating increased financing activities[33] Research and Development - The company received acceptance notifications for three new product applications from the National Medical Products Administration in August 2023[26] - The clinical study for the "Dermatitis Diagnostic Patch 01" was completed, and the Phase I clinical trial summary report was obtained in September 2023[26] - The company initiated a Phase I clinical trial for its "Fusarium oxysporum puncture solution" at Tongji Hospital, marking a significant step in its R&D efforts[42] - Research and development expenses for the current period are CNY 78,493,899.35, compared to CNY 76,318,393.79 in the previous period, reflecting a growth of 2.9%[29] Other Income and Expenses - The company reported a significant decrease in other income, which fell by ¥26,671,374.88, a reduction of 88.96% compared to the previous year[8] - The income tax expense for the period was 41,680,386.91, down from 59,598,740.47, reflecting a reduction of approximately 30.1%[48] - The other comprehensive income after tax attributable to the parent company was 8,112.20, down from 29,661.57, a decrease of approximately 72.7%[48] - The company reported a credit impairment loss of 2,949,561.24, an improvement from 4,161,731.15 in the previous period, indicating a reduction of about 29.1%[48] - The company experienced a fair value change loss of 1,572,973.11, compared to a gain of 1,035,426.10 in the previous period, reflecting a significant negative shift[48] - The company’s operating income from non-operating activities was 1,055,081.51, down from 2,226,515.29, a decrease of approximately 52.6%[48] - The company’s net loss from joint ventures and associates was 3,802,092.66, worsening from a loss of 2,550,309.13 in the previous period[48]